G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
94 hedge funds and large institutions have $863M invested in G1 Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 42 increasing their positions, 22 reducing their positions, and 14 closing their positions.
91% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 22
89% more capital invested
Capital invested by funds: $457M → $863M (+$406M)
64% more call options, than puts
Call options by funds: $401K | Put options by funds: $245K
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
1% more funds holding
Funds holding: 93 → 94 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$14.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$11.5M |
| 3 |
BlackRock
New York
|
+$11.2M |
| 4 |
JP Morgan Chase
New York
|
+$6.54M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$6.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$20.6M |
| 2 |
Morgan Stanley
New York
|
-$7.19M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$5.38M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$3.63M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.55M |
GTHX Hedge Fund Activity: Q2 2019 in Review
94 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q2 2019, worth a combined $863M — up 89% from $457M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new GTHX positions and 14 closed out — a net gain of 4 holders — while 42 added to existing stakes and 22 trimmed.
The largest buyer was Bellevue Group, opening a new position worth an estimated $14.1M. The largest seller was Bank of New York Mellon, cutting an estimated $20.6M.
- 94 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q2 2019, up from 93 in Q1 2019.
- Funds reported $863M of G1 Therapeutics, Inc. Common Stock stock for Q2 2019, up 89% quarter-over-quarter.
- 18 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q2 2019 and 14 closed out, a net change of +4 holders.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q2 2019 was Bellevue Group, an estimated $14.1M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q2 2019 was Bank of New York Mellon, an estimated $20.6M sold.
Based on aggregated 13F filings for Q2 2019.